Notch signaling in female cancers: a multifaceted node to overcome drug resistance.
Notch signaling
cancer stem cells
drug efflux
drug resistance
epithelial-to-mesenchymal transition
female-specific cancers
tumor microenvironment
Journal
Cancer drug resistance (Alhambra, Calif.)
ISSN: 2578-532X
Titre abrégé: Cancer Drug Resist
Pays: United States
ID NLM: 101738710
Informations de publication
Date de publication:
2021
2021
Historique:
received:
09
06
2021
revised:
29
07
2021
accepted:
03
08
2021
entrez:
18
5
2022
pubmed:
19
5
2022
medline:
19
5
2022
Statut:
epublish
Résumé
Drug resistance is one of the main challenges in cancer therapy, including in the treatment of female-specific malignancies, which account for more than 60% of cancer cases among women. Therefore, elucidating the underlying molecular mechanisms is an urgent need in gynecological cancers to foster novel therapeutic approaches. Notably, Notch signaling, including either receptors or ligands, has emerged as a promising candidate given its multifaceted role in almost all of the hallmarks of cancer. Concerning the connection between Notch pathway and drug resistance in the afore-mentioned tumor contexts, several studies focused on the Notch-dependent regulation of the cancer stem cell (CSC) subpopulation or the induction of the epithelial-to-mesenchymal transition (EMT), both features implicated in either intrinsic or acquired resistance. Indeed, the present review provides an up-to-date overview of the published results on Notch signaling and EMT- or CSC-driven drug resistance. Moreover, other drug resistance-related mechanisms are examined such as the involvement of the Notch pathway in drug efflux and tumor microenvironment. Collectively, there is a long way to go before every facet will be fully understood; nevertheless, some small pieces are falling neatly into place. Overall, the main aim of this review is to provide strong evidence in support of Notch signaling inhibition as an effective strategy to evade or reverse resistance in female-specific cancers.
Identifiants
pubmed: 35582386
doi: 10.20517/cdr.2021.53
pmc: PMC8992449
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
805-836Informations de copyright
© The Author(s) 2021.
Déclaration de conflit d'intérêts
All authors declared that there are no conflicts of interest.
Références
Front Cell Dev Biol. 2021 Mar 01;9:641469
pubmed: 33732706
Cancer Res. 2012 Jun 1;72(11):2768-79
pubmed: 22472119
Cancer Res. 2011 Sep 15;71(18):6030-9
pubmed: 21795478
J Cell Biol. 2009 Mar 9;184(5):621-9
pubmed: 19255248
J Physiol Pharmacol. 2017 Aug;68(4):555-564
pubmed: 29151072
Int J Cancer. 2019 Oct 1;145(7):1921-1934
pubmed: 30895619
Proc Natl Acad Sci U S A. 2014 Dec 16;111(50):E5429-38
pubmed: 25453096
Gynecol Oncol. 2020 May;157(2):386-391
pubmed: 32037195
Front Immunol. 2018 Apr 09;9:652
pubmed: 29686671
Oncogenesis. 2018 Aug 13;7(8):59
pubmed: 30100605
J Exp Med. 2007 Nov 26;204(12):2935-48
pubmed: 17984306
J Biochem. 2016 Mar;159(3):287-94
pubmed: 26711237
Exp Cell Res. 2018 May 15;366(2):161-171
pubmed: 29548748
Aust Fam Physician. 2006 May;35(5):309-12
pubmed: 16680209
J Immunol. 2009 Mar 15;182(6):3380-9
pubmed: 19265115
Int J Biochem Cell Biol. 2019 Apr;109:76-81
pubmed: 30772480
Updates Surg. 2017 Sep;69(3):313-317
pubmed: 28260181
Hum Genomics. 2009 Apr;3(3):281-90
pubmed: 19403462
J Exp Med. 2011 Sep 26;208(10):1931-5
pubmed: 21948802
Clin Cancer Res. 2013 Mar 15;19(6):1512-24
pubmed: 23340294
Cancer Res. 2011 Sep 15;71(18):6073-83
pubmed: 21803743
Oncotarget. 2016 Aug 23;7(34):55624-55638
pubmed: 27489349
Expert Opin Ther Targets. 2008 Sep;12(9):1139-65
pubmed: 18694380
Int J Cancer. 2018 Nov 1;143(9):2238-2249
pubmed: 29786136
Oncol Lett. 2019 Sep;18(3):2173-2178
pubmed: 31452720
Cells. 2019 Aug 22;8(9):
pubmed: 31443516
Clin Transl Med. 2013 Jan 17;2(1):3
pubmed: 23369605
J Transl Med. 2019 Jun 10;17(1):194
pubmed: 31182109
Cancer Med. 2016 Dec;5(12):3544-3554
pubmed: 27925454
J Clin Oncol. 2017 Apr 1;35(10):1061-1069
pubmed: 28045625
J Exp Clin Cancer Res. 2021 Apr 6;40(1):120
pubmed: 33823894
Science. 2004 Oct 8;306(5694):269-71
pubmed: 15472075
Mol Cancer Ther. 2018 May;17(5):1039-1050
pubmed: 29592882
Cancer Res. 2008 Nov 1;68(21):9087-95
pubmed: 18974155
PLoS One. 2009 Nov 11;4(11):e7695
pubmed: 19907646
J Exp Clin Cancer Res. 2018 Oct 19;37(1):256
pubmed: 30340507
Clin Breast Cancer. 2005 Dec;6(5):391-401
pubmed: 16381622
Exp Cell Res. 2019 Jul 15;380(2):141-148
pubmed: 31034805
J Hematol Oncol. 2020 May 26;13(1):60
pubmed: 32456660
Neuron. 1996 Jul;17(1):21-6
pubmed: 8755475
EMBO Mol Med. 2014 Jan;6(1):99-119
pubmed: 24357640
BMC Cancer. 2019 Apr 11;19(1):351
pubmed: 30975104
J Immunol. 2010 May 1;184(9):4673-8
pubmed: 20351182
Onco Targets Ther. 2020 Dec 14;13:12811-12827
pubmed: 33363386
Cell. 2011 Mar 4;144(5):646-74
pubmed: 21376230
Gynecol Oncol. 2017 Oct;147(1):158-166
pubmed: 28689667
PLoS One. 2015 Jul 24;10(7):e0134201
pubmed: 26207375
Life Sci. 2019 Nov 15;237:116952
pubmed: 31622608
Nat Neurosci. 2007 Jul;10(7):819-27
pubmed: 17589506
Proc Natl Acad Sci U S A. 2011 Dec 20;108(51):20778-83
pubmed: 22143792
Lancet. 2014 Oct 11;384(9951):1376-88
pubmed: 24767708
Front Cell Dev Biol. 2021 Feb 16;9:642352
pubmed: 33681228
Int J Cancer. 2015 Mar 1;136(5):E359-86
pubmed: 25220842
J Oncol. 2019 Jul 11;2019:8707053
pubmed: 31379945
Nat Rev Cancer. 2018 Nov;18(11):669-680
pubmed: 30228301
Lancet. 2003 Jun 28;361(9376):2217-25
pubmed: 12842378
Curr Drug Discov Technol. 2010 Mar;7(1):54-66
pubmed: 20156136
Int J Mol Sci. 2020 Dec 29;22(1):
pubmed: 33383646
Biochem Biophys Res Commun. 2014 Feb 21;444(4):670-5
pubmed: 24502949
Cell Immunol. 2019 Sep;343:103729
pubmed: 29397066
Br J Cancer. 2010 Jan 19;102(2):351-60
pubmed: 20010940
Cells. 2020 Sep 29;9(10):
pubmed: 33003540
Int J Biol Macromol. 2019 Apr 1;126:1318-1325
pubmed: 30244128
Breast Cancer Res. 2011 Jun 10;13(3):211
pubmed: 21672282
Front Cell Dev Biol. 2020 Dec 15;8:592616
pubmed: 33384996
Nat Med. 1995 Jun;1(6):578-82
pubmed: 7585126
Br J Cancer. 2013 Nov 12;109(10):2587-96
pubmed: 24129237
Lancet Infect Dis. 2007 Jul;7(7):453-9
pubmed: 17597569
Stem Cells Int. 2019 Jan 6;2019:6264931
pubmed: 30723507
Cancer Res. 2011 Jun 1;71(11):3991-4001
pubmed: 21498635
BMC Cancer. 2015 Dec 16;15:957
pubmed: 26673416
Nat Rev Cancer. 2005 Apr;5(4):275-84
pubmed: 15803154
Cell Rep. 2015 Sep 29;12(12):1968-77
pubmed: 26387946
Q J Nucl Med Mol Imaging. 2013 Dec;57(4):312-21
pubmed: 24322788
Drug Resist Updat. 2020 Dec;53:100715
pubmed: 32679188
Cancer Sci. 2010 Sep;101(9):1977-83
pubmed: 20624166
Nat Rev Clin Oncol. 2017 Oct;14(10):611-629
pubmed: 28397828
Nature. 2019 Jan;565(7738):192-197
pubmed: 30598546
J Cell Physiol. 2013 Sep;228(9):1854-62
pubmed: 23459996
Cancer Res. 2015 Oct 1;75(19):4086-96
pubmed: 26377940
Cancer Treat Rev. 2013 Apr;39(2):153-60
pubmed: 22595680
Curr Opin Obstet Gynecol. 2015 Feb;27(1):58-65
pubmed: 25502429
Cancer Res. 2010 Jan 15;70(2):709-18
pubmed: 20068161
Oncogene. 2008 Oct 2;27(44):5833-44
pubmed: 18560356
Cancers (Basel). 2015 Dec 11;7(4):2443-58
pubmed: 26690480
J Glob Oncol. 2016 Aug 17;3(4):400-408
pubmed: 28831448
Mol Carcinog. 2016 Jul;55(7):1196-209
pubmed: 26207830
Eur J Cell Biol. 2011 Jun-Jul;90(6-7):572-81
pubmed: 21126799
Int J Biochem Cell Biol. 2010 Jul;42(7):1115-22
pubmed: 20348013
Nature. 2019 Nov;575(7782):299-309
pubmed: 31723286
Tumour Biol. 2016 Apr;37(4):5063-74
pubmed: 26546434
Clin Cancer Res. 2018 Sep 15;24(18):4566-4578
pubmed: 29895705
Cell Mol Life Sci. 2009 Jan;66(1):43-61
pubmed: 18759128
Front Immunol. 2018 Aug 20;9:1718
pubmed: 30967879
Am J Pathol. 2010 Sep;177(3):1087-94
pubmed: 20671266
Nat Med. 2017 Oct 6;23(10):1124-1134
pubmed: 28985214
Life Sci. 2019 Oct 1;234:116781
pubmed: 31430455
Invest New Drugs. 2019 Aug;37(4):722-730
pubmed: 30591982
Oncogene. 2010 Jan 14;29(2):201-13
pubmed: 19838210
Pharmacol Rev. 2015;67(2):441-61
pubmed: 25769965
Cancer Cell. 2017 Dec 11;32(6):731-747.e6
pubmed: 29232552
Nat Rev Dis Primers. 2016 Aug 25;2:16061
pubmed: 27558151
Cell Commun Signal. 2021 Feb 15;19(1):19
pubmed: 33588867
Ecancermedicalscience. 2014 Sep 25;8:465
pubmed: 25371706
Tumour Biol. 2016 Oct 14;:
pubmed: 27743379
J Exp Clin Cancer Res. 2019 Aug 30;38(1):382
pubmed: 31470883
Oncogenesis. 2018 May 25;7(5):42
pubmed: 29795369
CA Cancer J Clin. 2014 May-Jun;64(3):186-94
pubmed: 24647877
Annu Rev Pathol. 2017 Jan 24;12:245-275
pubmed: 27959635
Biochem Biophys Res Commun. 2020 May 21;526(1):158-164
pubmed: 32201081
Exp Cell Res. 2013 May 15;319(9):1281-8
pubmed: 23328307
Cancer Epidemiol. 2015 Dec;39 Suppl 1:S120-38
pubmed: 26589774
J Biol Chem. 2013 Sep 20;288(38):27343-27357
pubmed: 23902763
Cancer Epidemiol. 2012 Jun;36(3):237-48
pubmed: 22459198
Cancer Cell. 2013 Jun 10;23(6):839-52
pubmed: 23684459
Reprod Biol Endocrinol. 2010 Dec 01;8:147
pubmed: 21122138
Nat Rev Cancer. 2018 Jun;18(6):359-376
pubmed: 29700396
Cell Oncol (Dordr). 2021 Aug;44(4):715-737
pubmed: 33835425
J Cancer. 2017 Sep 20;8(16):3331-3342
pubmed: 29158806
Gynecol Oncol. 2004 Oct;95(1):133-8
pubmed: 15385122
Adv Exp Med Biol. 2020;1223:1-16
pubmed: 32030682
Oncotarget. 2017 Jan 17;8(3):4008-4042
pubmed: 28008141
Adv Exp Med Biol. 2012;727:15-36
pubmed: 22399336
Mol Cancer. 2019 Mar 30;18(1):70
pubmed: 30927908
Oncogene. 2018 Apr;37(14):1857-1868
pubmed: 29348460
Pol J Pathol. 2018;69(3):234-242
pubmed: 30509050
Oncotarget. 2016 Oct 18;7(42):68229-68241
pubmed: 27626163
Biochem Biophys Res Commun. 2018 Jan 1;495(1):1081-1088
pubmed: 29170132
Front Immunol. 2018 Jun 04;9:1288
pubmed: 29915603
Oncogene. 2008 Sep 1;27(38):5148-67
pubmed: 18758484
Cancer Epidemiol Biomarkers Prev. 2017 Apr;26(4):444-457
pubmed: 28223433
Gynecol Oncol. 2019 Apr;153(1):135-148
pubmed: 30686552
Mol Biol Rep. 2019 Oct;46(5):5645-5659
pubmed: 31280421
Cell Metab. 2018 Jun 05;27(6):1357
pubmed: 29874570
Cancer Res. 2009 Mar 15;69(6):2400-7
pubmed: 19276344
Cancer Cell Int. 2020 Jul 28;20:344
pubmed: 32742191
J Cell Mol Med. 2019 Jun;23(6):4005-4018
pubmed: 30993885
Lancet. 2019 Jan 12;393(10167):169-182
pubmed: 30638582
Cancer. 2007 Aug 15;110(4):876-84
pubmed: 17620276
J Clin Oncol. 2004 Aug 15;22(16):3408-19
pubmed: 15199089
Eur Rev Med Pharmacol Sci. 2019 Jan;23(2):522-529
pubmed: 30720159
Nat Rev Drug Discov. 2021 Feb;20(2):125-144
pubmed: 33293690
Drug Resist Updat. 2018 Jan;36:47-76
pubmed: 29499837
J Cancer Res Clin Oncol. 2014 Apr;140(4):525-36
pubmed: 24114288
Cancer Res. 2011 Jul 15;71(14):4888-97
pubmed: 21646470
Toxicol Sci. 2018 Aug 1;164(2):527-538
pubmed: 29718440
Cancer Lett. 2017 Feb 1;386:168-178
pubmed: 27887917
J Cancer Stem Cell Res. 2016;4:
pubmed: 27668267
Breast Cancer (Dove Med Press). 2020 Nov 11;12:211-229
pubmed: 33204149
J Ovarian Res. 2014 Nov 04;7:95
pubmed: 25366565
Biomedicines. 2018 Nov 01;6(4):
pubmed: 30388742
Chin J Cancer Res. 2011 Jun;23(2):140-6
pubmed: 23482909
Mol Cancer. 2015 Feb 03;14:28
pubmed: 25645291
Protoplasma. 2020 May;257(3):901-910
pubmed: 31897811
Cell Adh Migr. 2019 Dec;13(1):203-218
pubmed: 31096822
Gynecol Oncol. 2013 Jul;130(1):200-6
pubmed: 23542683
Invest New Drugs. 2019 Jun;37(3):461-472
pubmed: 30229512
Int J Gynecol Cancer. 2010 Oct;20(11 Suppl 2):S49-51
pubmed: 21053528
Epidemiology. 2006 Jul;17(4):469-72
pubmed: 16755263
Int J Mol Sci. 2020 May 02;21(9):
pubmed: 32370233
Molecules. 2021 Mar 17;26(6):
pubmed: 33802884
Breast Cancer Res Treat. 2017 Nov;166(1):95-107
pubmed: 28730338
Eur J Gynaecol Oncol. 2007;28(3):193-5
pubmed: 17624085
Nat Rev Cancer. 2013 Oct;13(10):714-26
pubmed: 24060863
J Cancer. 2020 Apr 6;11(13):3846-3857
pubmed: 32328189
Lancet. 2015 Mar 14;385(9972):977-1010
pubmed: 25467588
J Clin Oncol. 2008 Jul 10;26(20):3324-30
pubmed: 18612148
Oncogene. 2008 Jul 3;27(29):4086-95
pubmed: 18332865
Lancet Oncol. 2010 Dec;11(12):1172-83
pubmed: 21126687
Front Pharmacol. 2020 Jun 17;11:904
pubmed: 32625096
Clin Cancer Res. 2016 Jun 1;22(11):2675-83
pubmed: 26758558
Int Immunopharmacol. 2011 Jul;11(7):808-15
pubmed: 21426948
Lancet. 2015 Sep 12;386(9998):1038-9
pubmed: 26382993
Int J Oncol. 2013 Oct;43(4):1194-204
pubmed: 23921511
CA Cancer J Clin. 2016 Jan-Feb;66(1):7-30
pubmed: 26742998
Cell Cycle. 2017 Mar 19;16(6):533-535
pubmed: 28103135
Cell Div. 2016 Sep 27;11:12
pubmed: 27708688
Cells. 2020 Aug 11;9(8):
pubmed: 32796631
J Exp Clin Cancer Res. 2019 Jun 3;38(1):234
pubmed: 31159852
Cell Oncol (Dordr). 2019 Apr;42(2):157-171
pubmed: 30603978
J Biol Chem. 1997 May 30;272(22):14110-4
pubmed: 9162037
Front Oncol. 2019 Sep 19;9:913
pubmed: 31608227
Cancer Res. 2013 Oct 15;73(20):6194-205
pubmed: 23943800
Clin Cancer Res. 2009 Mar 15;15(6):2010-21
pubmed: 19276287
EMBO Mol Med. 2013 Mar;5(3):384-96
pubmed: 23495140
NPJ Breast Cancer. 2018 Aug 6;4:20
pubmed: 30109262
Science. 1999 Apr 30;284(5415):770-6
pubmed: 10221902
Transl Cancer Res. 2019 Apr;8(2):379-388
pubmed: 35116770
Oncol Lett. 2013 Dec;6(6):1673-1680
pubmed: 24260061
Stem Cells Int. 2016;2016:2498764
pubmed: 26880941
J Hematol Oncol. 2019 Jul 12;12(1):76
pubmed: 31300030
Oncotarget. 2016 Sep 27;7(39):63611-63628
pubmed: 27613838
Med Sci Monit. 2018 Jun 14;24:4046-4053
pubmed: 29899322
Oncogene. 2008 Aug 28;27(37):5019-32
pubmed: 18469855
Obstet Gynecol. 2019 Jul;134(1):17-29
pubmed: 31188310
Cancer Lett. 2013 Jan 28;328(2):261-70
pubmed: 23041621
Cancer Res. 2016 Jan 15;76(2):440-52
pubmed: 26676751
Cancer Lett. 2019 Jan;440-441:156-167
pubmed: 30336197
Front Oncol. 2020 Feb 27;10:221
pubmed: 32175278
Curr Oncol Rep. 2018 Apr 2;20(5):40
pubmed: 29611060
J Nucl Med. 2016 Feb;57 Suppl 1:9S-16S
pubmed: 26834110
Endocrinology. 2019 Aug 1;160(8):2015-2023
pubmed: 31271419
Front Cell Dev Biol. 2020 Nov 03;8:583087
pubmed: 33224949
Mol Cell Endocrinol. 2017 Jan 15;440:125-137
pubmed: 27908834
Lancet Oncol. 2014 Jan;15(1):23-34
pubmed: 24314615
Cancers (Basel). 2018 Oct 30;10(11):
pubmed: 30380719
Cancer Res. 2016 Jun 1;76(11):3156-65
pubmed: 27197152
Stem Cells Transl Med. 2013 Mar;2(3):233-42
pubmed: 23408105
PLoS One. 2020 Oct 22;15(10):e0240533
pubmed: 33091036
Cell. 2014 Oct 23;159(3):499-513
pubmed: 25417103
Mol Cancer Ther. 2016 Jun;15(6):1344-52
pubmed: 27009216
Eur J Cancer. 2020 Mar;127:207-223
pubmed: 31980322
Adv Exp Med Biol. 2018;1066:339-354
pubmed: 30030835
Ann Biomed Eng. 2020 Jul;48(7):1864-1884
pubmed: 31686312
Anticancer Res. 2010 Oct;30(10):3853-67
pubmed: 21036696
Cancer Cell. 2013 Mar 18;23(3):272-3
pubmed: 23518345
Nat Rev Cancer. 2011 May;11(5):338-51
pubmed: 21508972
Breast Cancer Res Treat. 2002 Nov;76(1):27-36
pubmed: 12408373
Clin Cancer Res. 2011 Sep 1;17(17):5674-85
pubmed: 21753153
Cancer Med. 2019 Aug;8(9):4380-4388
pubmed: 31215145
Cancer Immunol Immunother. 2017 Jun;66(6):753-764
pubmed: 28283696
Free Radic Biol Med. 2020 Jan;146:306-323
pubmed: 31536771
Breast J. 2012 Jul-Aug;18(4):345-50
pubmed: 22607041
J Ovarian Res. 2019 Dec 06;12(1):120
pubmed: 31810474
Protein Cell. 2018 Aug;9(8):674-692
pubmed: 28929459
Cell Signal. 2016 Aug;28(8):838-49
pubmed: 27075926
CA Cancer J Clin. 2015 Mar;65(2):87-108
pubmed: 25651787
Cancer Res. 2017 Apr 15;77(8):1927-1941
pubmed: 28202520
Eur J Med Chem. 2017 Oct 20;139:961-981
pubmed: 28886509
Cancer Biol Med. 2017 Feb;14(1):9-32
pubmed: 28443200
PLoS One. 2013;8(2):e56840
pubmed: 23457626
Breast Cancer Res Treat. 2012 Oct;135(3):647-54
pubmed: 22864804
Proc Natl Acad Sci U S A. 2012 Oct 23;109(43):E2939-48
pubmed: 23019585
Transl Oncol. 2018 Oct;11(5):1259-1270
pubmed: 30119050
Cancers (Basel). 2014 Sep 05;6(3):1769-92
pubmed: 25198391
Nat Commun. 2016 Dec 12;7:13719
pubmed: 27941799
Vaccine. 2012 Nov 20;30 Suppl 5:F24-33
pubmed: 23199964
J Cell Commun Signal. 2015 Mar;9(1):5-13
pubmed: 25711903
Cancers (Basel). 2019 Jul 22;11(7):
pubmed: 31336602
J Cancer. 2020 May 18;11(15):4474-4494
pubmed: 32489466
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
Nat Rev Clin Oncol. 2011 Feb;8(2):97-106
pubmed: 21151206
Front Oncol. 2018 Dec 04;8:575
pubmed: 30564555
Biochem Biophys Res Commun. 2015 Jun 5;461(3):525-32
pubmed: 25911324
J Cell Sci. 2013 May 15;126(Pt 10):2135-40
pubmed: 23729744
Cell. 2016 Jun 30;166(1):21-45
pubmed: 27368099
Physiol Rev. 2017 Oct 1;97(4):1235-1294
pubmed: 28794168
Oncogene. 2018 Aug;37(33):4489-4504
pubmed: 29743588
Lancet Oncol. 2015 Jan;16(1):36-46
pubmed: 25467404
Oncotarget. 2017 Jan 10;8(2):2320-2328
pubmed: 27906684
Biochim Biophys Acta Rev Cancer. 2021 Jan;1875(1):188446
pubmed: 33058997
Cell. 2010 Mar 19;140(6):883-99
pubmed: 20303878
BMC Cancer. 2015 Sep 11;15:634
pubmed: 26362310
Breast Cancer Res Treat. 2013 Apr;138(3):665-73
pubmed: 23546552
Front Oncol. 2018 Nov 20;8:518
pubmed: 30515368
J R Soc Interface. 2017 Nov;14(136):
pubmed: 29187638
Pharmacol Rep. 2020 Oct;72(5):1125-1151
pubmed: 32700248
Nat Rev Cancer. 2018 Jul;18(7):452-464
pubmed: 29643473
Cancer Res. 2007 Mar 1;67(5):1879-82
pubmed: 17332312
Proc Natl Acad Sci U S A. 2008 Apr 29;105(17):6392-7
pubmed: 18427106
Cell. 1997 Jul 25;90(2):281-91
pubmed: 9244302
Nat Commun. 2020 Jan 21;11(1):404
pubmed: 31964880
Cells. 2020 Jun 20;9(6):
pubmed: 32575680
Front Immunol. 2018 Jul 16;9:1649
pubmed: 30061899
Ann Epidemiol. 2015 Aug;25(8):564-8
pubmed: 25911981
Cancer Biol Ther. 2018 Feb 1;19(2):113-119
pubmed: 27791463
N Engl J Med. 2006 Jan 5;354(1):34-43
pubmed: 16394300
Nat Rev Mol Cell Biol. 2006 Sep;7(9):678-89
pubmed: 16921404
J Control Release. 2012 Oct 28;163(2):136-44
pubmed: 22940126
Int J Gynecol Cancer. 2003 Sep-Oct;13(5):673-7
pubmed: 14675353
Breast Cancer Res. 2016 Aug 11;18(1):84
pubmed: 27515302
Int J Cancer. 2020 Jul 15;147(2):490-504
pubmed: 32020593